capecitabine + lapatinib + trebananib

This is a theoretical combination of three distinct drugs: lapatinib, an oral, reversible, dual inhibitor of epidermal growth factor receptor ErbB1 (EGFR) and human epidermal growth factor receptor type 2 ErbB2 (HER2); capecitabine, an oral chemotherapy agent that is metabolized to 5-FU (5-fluorouracil) in the body; and trebananib, a peptide-Fc fusion protein that neutralizes the receptor-ligand interaction between Tie2 and angiopoietin-1/2, functioning as an angiogenesis inhibitor. While the combination of lapatinib and capecitabine is FDA-approved for treating advanced or metastatic HER2-positive breast cancer, the specific three-drug combination of capecitabine + lapatinib + trebananib does not appear to be an established or widely studied regimen based on the provided search results.

Other names

trebananib + capecitabine + lapatinib